Nathan D Seligson

Nathan D Seligson, Pharm.D.

Clinical Assistant Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (904) 244-9590
Business Email:

About Nathan D Seligson

Dr. Seligson earned his Doctor of Pharmacy degree from the University of South Florida prior to completing a pharmacy practice residency. Dr. Seligson then completed a post-doctoral fellowship in translational hematology/oncology focused on precision medicine in sarcoma.

Dr. Seligson is a Clinical Assistant Professor in the Department of Pharmacotherapy and Translational Research. His clinical practice includes activities as a clinical pharmacogenomics specialist and hematology/oncology research scientist at Nemours Children’s Specialty Care in Jacksonville, Florida.

Dr. Seligson has been published in as first author in leading journals including: JAMA Open Network, The Oncologist, and npj Precision Medicine. His current research includes work to better understand cancer biology and tumor evolution in order to provide actionable molecular subtyping and pharmacogenomic therapy guidance in sarcoma.

Research Profile

Open Researcher and Contributor ID (ORCID)



Adding the second T: Elevating STAR to START for behavioral interviewing.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 78(1):18-21 [DOI] 10.1093/ajhp/zxaa356. [PMID] 33155021.
Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Clinical pharmacology and therapeutics. 109(2):334-342 [DOI] 10.1002/cpt.1946. [PMID] 32535906.
Evaluation of the timing of MRSA PCR nasal screening: How long can a negative assay be used to rule out MRSA-positive respiratory cultures?
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 78(Supplement_2):S57-S61 [DOI] 10.1093/ajhp/zxab109. [PMID] 33788910.
Key Considerations for Selecting a Genomic Decision Support Platform for Implementing Pharmacogenomics.
Clinical pharmacology and therapeutics. 110(3):555-558 [DOI] 10.1002/cpt.2328. [PMID] 34254671.
Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target.
NPJ precision oncology. 5(1) [DOI] 10.1038/s41698-021-00177-0. [PMID] 34021224.
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
Annals of Pharmacotherapy. 55(7):921-931 [DOI] 10.1177/1060028020966548.
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation
Cancers. 13(7) [DOI] 10.3390/cancers13071566. [PMID] 33805415.
Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.
Anticancer research. 40(10):5707-5713 [DOI] 10.21873/anticanres.14585. [PMID] 32988896.
Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives.
Cell death discovery. 6 [DOI] 10.1038/s41420-020-0286-z. [PMID] 32566256.
Integration of EMT and cellular survival instincts in reprogramming of programmed cell death to anastasis.
Cancer metastasis reviews. 39(2):553-566 [DOI] 10.1007/s10555-020-09866-x. [PMID] 32020420.
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity
Journal of the American Medical Informatics Association. 27(11):1808-1812 [DOI] 10.1093/jamia/ocaa159. [PMID] 32885823.
BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma.
The oncologist. 24(7):973-979 [DOI] 10.1634/theoncologist.2018-0448. [PMID] 30541756.
Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma.
JAMA network open. 2(10) [DOI] 10.1001/jamanetworkopen.2019.12416. [PMID] 31577358.
Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma.
The oncologist. 24(7):989-996 [DOI] 10.1634/theoncologist.2019-0047. [PMID] 31019022.
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma.
Oncotarget. 10(55):5671-5679 [DOI] 10.18632/oncotarget.27144. [PMID] 31620242.
XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
Molecular carcinogenesis. 58(12):2327-2339 [DOI] 10.1002/mc.23121. [PMID] 31544312.
Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
The Annals of pharmacotherapy. 52(5):439-445 [DOI] 10.1177/1060028017749214. [PMID] 29241342.


Post-doctoral Fellowship in Translational Hematology/Oncology
2016-2019 · The Ohio State University
PGY1 Pharmacy Practice Residency
2015-2016 · Baptist Memorial Healthcare – Memphis
2011-2015 · University of South Florida
2007-2011 · University of Central Florida

Teaching Profile

Courses Taught
PHA6136 Clinical Applications of Precision Medicine: Oncology
PHA6935 Selected Topics in Pharmacy
PHA5012 App Personalized Med

Contact Details

(904) 244-9590